Antibe inks anti-inflam/pain product licensing deal with Knight Therapeutics

Canadian healthcare company Antibe Therapeutics (TSXV: ATE) has signed an exclusive long-term license and distribution agreement with Knight Therapeutics (TSX: GUD) for Antibe’s anti-inflammatory and pain drugs, ATB-346, ATB-352 and ATB-340, as well as the rights to other future Antibe prescription drugs.

Under the terms of the deal, Antibe has granted Knight, a leading Canadian specialty pharmaceutical company, the exclusive commercial rights for drug candidates and other future prescription drugs in Canada, Israel, Romania, Russia and sub-Saharan Africa.

Antibe is entitled to royalties on annual sales, along with the potential for C$10 million ($7.5 million) in payments for sales-based milestones. Antibe considers this a favorable royalty scenario given its competitive anticipated cost-of-goods structure. The global market for non-steroidal anti-inflammatory and pain drugs is more than $12 billion annually, despite serious side effects for the currently marketed drugs, especially when taken over the long-term. Antibe’s drug candidates are novel and patent-protected, and are designed to be safer versions of drugs currently on the market, the company stated.